



Source: LASCCO SA and Abionic SA

LASCCO and Abionic Announce a Licensing Agreement with Fapon for PSP Sepsis Diagnosis in China

OCTOBER 26, 2023.

LASCCO SA and Abionic SA, Epalinges, Switzerland, announced today that they have signed a licensing agreement with global life science company, Fapon for the use of the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China.

This agreement initiates a strategic cooperation between LASCCO, Fapon and Abionic SA, LASCCO's partner since 2015 for the development and commercialization of PSP on Abionic's abioSCOPE® device.

Under this agreement, Fapon will engage in the development and commercialization of PSP on its chemiluminescent immunoassay (CLIA) analyzer within the Chinese market. In 2022, Abionic's abioSCOPE® device and PSP test were granted the IVDR certification for in-vitro diagnostics. Since then, the PSP test has been commercially deployed in 20+ countries and is already widely used to diagnose ICU patients in several European hospitals, providing clinicians with a clear result in all at-risk patients in 5 minutes. Moreover, Abionic is in final preparation of preparing an application for 510(k) clearance with the FDA in the United States.

This strategic partnership will usher in a significant breakthrough in the medical field, removing barriers to early sepsis diagnosis. Performing PSP testing on high-risk individuals can flag potential sepsis before the onset of clinical symptoms. Early detection enables to rule in / rule out for critical care, to treat in a timely manner which is tightly linked to reduced risks of organ dysfunction and improved survival rates, and to optimize allocation of medical resources.

About PSP

PSP is an acute-phase protein secreted by pancreatic acinar cells. Its levels correlate with the presence and with the severity of sepsis. Sufficient evidence has shown that PSP exhibits great accuracy as an early warning sign of sepsis. The PSP level in the blood shows a significant upward trend three days prior to the clinical diagnosis of sepsis [2,3], even in inflammatory confounding situations such as sterile inflammation and inhalation injury in burnt patients or post-trauma and post-surgery inflammatory host responses [4,5].

About LASCCO

LASCCO SA is a biomedical-technology company based at the Biopôle of Lausanne, Switzerland. The primary objective of LASCCO is to develop promising discovery-stage therapeutics and

diagnostics stemming from research institute labs up to advanced clinical stage. LASCCO has developed in-depth expertise in the fields of critical care and emergency medicine, and its portfolio is currently composed of innovative products aiming at fighting sepsis and treating severe bacterial and viral infections.

Follow us on LinkedIn (LASCCO) or visit our website www.lascco.com.

About FAPON

Fapon is a global leading life sciences company dedicated to providing integrated solutions and services for diagnostics, biopharma and biotherapy. Integrating a one-stop solution on raw materials, reagents and innovative open instrument platforms, the Company has grown into a leading supplier in in-vitro diagnostics. Fapon boasts advanced innovations in therapeutics technologies and AI algorithm platforms with data insights that contribute to a better and healthier world. Supported by its strong global R&D, manufacturing, sales and service network, Fapon's products have established presence in 68 countries and regions, serving more than 2,500 business partners worldwide.

Follow us on LinkedIn (Fapon) or visit our website www.faponbiotech.com.

About ABIONIC

Abionic, which was awarded with the Swiss Medtech Award 2023, commercializes a revolutionary nanofluidic technology that provides healthcare professionals with a fast, simple and universal diagnostic tool. Abionic's cutting-edge nanotechnology enhances the efficiency and versatility of standard ELISA tests to provide optimal point-of-care (POC) treatment options by reducing current biological measurement techniques from the macroscopic to the nanoscale in a multi-analyte environment.

Abionic's in vitro diagnostics platform delivers ultra-fast, laboratory-quality results from a single drop of patient sample to the POC, enabling personalized diagnostics and opening the window of opportunity for immediate treatment. The company is mainly active in acute and primary care.

Follow us on LinkedIn (Abionic) or visit our website <https://www.abionic.com/>.

References

1. Kumar A, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest*. 2009 Nov;136(5):1237-1248.
2. Niggemann P, et al. Incidence and Time Point of Sepsis Detection as Related to Different Sepsis Definitions in Severely Burned Patients and Their Accompanying Time Course of Pro-Inflammatory Biomarkers. *J Pers Med*. 2021 Jul 23;11(8):701.
3. Klein HJ, et al. Pancreatic Stone Protein Predicts Sepsis in Severely Burned Patients Irrespective of Trauma Severity: A Monocentric Observational Study. *Ann Surg*. 2021 Dec 1;274(6):e1179-e1186.
4. Klein HJ, et al. Expression of Pancreatic Stone Protein is Unaffected by Trauma and Subsequent Surgery in Burn Patients. *World J Surg*. 2020 Sep;44(9):3000-3009.
5. Gukasjan R, et al. Pancreatic stone protein predicts outcome in patients with peritonitis in the ICU. *Crit. Care Med* 2013 Apr;41(4):1027-36.